ArticleClinical and experimental immunology2018
Infusion of ex-vivo expanded human TCR-αβ
Article in Clinical and experimental immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Beyond CAR-T and oncology: broadening chimeric antigen receptor technologies across cell types and diseases.Precision clinical medicine · 2026Review
- Single-cell atlas of rhesus monkey testis reveals aging- and season-dependent regulation of spermatogenesis and microenvironment homeostasis.International journal of biological sciences · 2026Article
- (TCRαβCells · 2025Review
- Single-cell RNA sequencing of human double-negative T cells reveals a favorable cellular signature for cancer therapy.Journal for immunotherapy of cancer · 2025Article
- Purinergic signaling by TCRαβScience bulletin · 2025Article
- Association of TCRαβFrontiers in immunology · 2025Article
- Bone marrow immune cells and drug resistance in acute myeloid leukemia.Experimental biology and medicine (Maywood, N.J.) · 2025Review
- Application of deep learning models on single-cell RNA sequencing analysis uncovers novel markers of double negative T cells.Scientific reports · 2024Article
- Identification of immune traits associated with neurodevelopmental disorders by two-sample Mendelian randomization analysis.BMC psychiatry · 2024Article
- CD19-CAR-DNT cells (RJMty19) in patients with relapsed or refractory large B-cell lymphoma: a phase 1, first-in-human study.EClinicalMedicine · 2024Article
- Double-Negative T (DNT) Cells in Patients with Systemic Lupus Erythematosus.Biomedicines · 2024Review
- CAR immunotherapy in autoimmune diseases: promises and challenges.Frontiers in immunology · 2024Review
- Distinct characteristics of unique immunoregulatory canine non-conventional TCRαβFrontiers in immunology · 2024Article
- Targeting T-cell malignancies using allogeneic double-negative CD4-CAR-T cells.Journal for immunotherapy of cancer · 2023Article
- Double-negative T cells: a promising avenue of adoptive cell therapy in transplant oncology.Journal of Zhejiang University. Science. B · 2023Article
- IL-33 promotes double negative T cell survival via the NF-κB pathway.Cell death & disease · 2023Article
- Adoptive Cell Therapy for T-Cell Malignancies.Cancers · 2022Review
- Insights into mechanisms of graft-versus-host disease through humanised mouse models.Bioscience reports · 2022Review
- Expansion of Double-Negative T Cells in Patients before Liver Transplantation Correlates with Post-Transplant Infections.Journal of clinical medicine · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Despite the demonstration of potent immunosuppressive function of T cell receptor (TCR)-αβ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.